<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857441</url>
  </required_header>
  <id_info>
    <org_study_id>CRF8025</org_study_id>
    <nct_id>NCT00857441</nct_id>
  </id_info>
  <brief_title>Drug-eluting Balloon in Bifurcations Trial</brief_title>
  <acronym>DEBIUT</acronym>
  <official_title>A Prospective Three-arm Multi-center Study to Investigate Procedural, Clinical and Angiographic Outcomes Using a Drug Eluting Balloon Versus a Standard Balloon in Combination With a Bare Metal Stent and a DES Stent, Following the Provisional Side Branch T-stenting Approach, in Patients With Complex Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the DEBIUT study is to assess procedural, clinical and angiographic outcomes&#xD;
      of:&#xD;
&#xD;
        1. Provisional T-stenting use for dilation the Paclitaxel-eluting PCI-balloon (DiorTM) in&#xD;
           comparison to dilation with a standard balloon prior to the implant of the Liberty Bare&#xD;
           Metal Stent in bifurcation lesions (with side branch involvement).&#xD;
&#xD;
        2. Comparison of the results above with the results of using a standard balloon prior to&#xD;
           provisional T-stenting with the Paclitaxel-eluting stent TaxusTM LibertéTM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Side branch angiographic Late Lumen Loss (expressed in millimeters) measured by Quantitative Coronary Analysis (QCA)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Angiographic coronary or cerebral Events (MACCE)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atherosclerosis</condition>
  <condition>Stable Angina</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Dior balloon and implant of Liberté Bare Metal Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of standard balloon and implant of Liberté Bare Metal Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting balloon</intervention_name>
    <description>Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Dior (EuroCor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liberté</intervention_name>
    <description>Bare metal stent</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Liberté (Boston Scientific)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTCA balloon catheter</intervention_name>
    <description>Percutaneous transluminal coronary angioplasty catheter</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Any PTCA catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus</intervention_name>
    <description>Paclitaxel eluting stent</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Taxus Liberté (Boston scientific)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable angina pectoris (CCS class 1,2,3,4) or unstable angina and documented ischemia&#xD;
             or silent ischemia&#xD;
&#xD;
          -  Patients eligible for coronary revascularisation&#xD;
&#xD;
          -  The target bifurcation lesion has a major native coronary artery (&gt;2.5mm) with a&#xD;
             stenosis &gt; 50% (on visual assessment) located at a side branch (&gt;2mm)&#xD;
&#xD;
          -  Patient must be acceptable for CABG&#xD;
&#xD;
          -  De novo lesion&#xD;
&#xD;
          -  The main vessel lesion can be covered by one stent (up to 32mm)&#xD;
&#xD;
          -  Only one target lesion can be included in the study: other lesions in different&#xD;
             vessels are successfully treated before the treatment of the target lesion (residual&#xD;
             stenosis &lt;30%, stent well deployed, no residual dissection, normal TIMI flow, no chest&#xD;
             pain, ECG unchanged compared to pre-procedural ECG)&#xD;
&#xD;
          -  Signed patients informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to give informed consent&#xD;
&#xD;
          -  Patients with a previous PCI in the target vessel&#xD;
&#xD;
          -  Patients with in stent restenosis of target lesion&#xD;
&#xD;
          -  Left ventricular ejection fraction more than 30%&#xD;
&#xD;
          -  Patients with left main disease&#xD;
&#xD;
          -  Severe calcifications with an undilatable lesion during balloon predilatation&#xD;
&#xD;
          -  History of bleeding diathesis&#xD;
&#xD;
          -  Untreated significant lesion greater than 50% diameter stenosis remaining proximal or&#xD;
             distal to the target intervention.&#xD;
&#xD;
          -  Patient has suffered a stroke or TIA within the past 3 months&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Any major surgery planned or required during the next 6 months&#xD;
&#xD;
          -  Acute Myocardial Infarction&#xD;
&#xD;
          -  Only one target lesion can be included in the study&#xD;
&#xD;
          -  Allergy to contrast and/or required anti-platelet medication&#xD;
&#xD;
          -  Patients unwilling to return for follow-up at 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter Stella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oost-Limburg Ziekenhuis</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gasthuisberg Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 cx</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Prof. Pieter Stella</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

